Dermatol. praxi. 2007;1(2):74-76

Pemphigus erythematosus

MUDr. Linda Bláhová1, MUDr. Alena Machovcová MBA1, MUDr. Vít Campr2, doc. MUDr. Lumír Pock CSc3
1 Dermatovenerologické oddělení, FN Motol, Praha
2 Ústav patologie a molekulární medicíny 2. LF UK a FN Motol, Praha
3 Dermatohistopatologická laboratoř Praha

Kazuistika popisuje případ 33leté ženy s několik let trvajícími krustózními projevy na obličeji, na horní polovině trupu, méně na končetinách a s opakovaně pozitivními ANA protilátkami v séru. Klinická diagnóza vzácného puchýřnatého onemocnění (pemphigus erythematosus) byla stanovena v roce 2005 histopatologickým a imunofluorescenčním vyšetřením. Pacientka je léčena kombinovanou imunosupresivní terapií, která onemocnění stabilizovala, avšak relapsy onemocnění se nepravidelně objevují. Cílem tohoto článku je upozornit na vzácnější variantu puchýřnatého onemocnění.

Published: June 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bláhová L, Machovcová A, Campr V, Pock L. Pemphigus erythematosus. Dermatol. praxi. 2007;1(2):74-76.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aghassi D, Dover JS. Pemphigus foliaceus induced by psoralen-UVA. Arch Dermatol 1998; 134 (10): 1300-1301. Go to original source... Go to PubMed...
    2. Ahmed AR, Sami N. Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy. J Am Acad Dermatol 2002; 46 (1): 42-49. Go to original source... Go to PubMed...
    3. Arenberger P. a kol. Nemoci s tvorbou puchýřů. Praha: Hutnig a Beneš, 1999: 32-33.
    4. Brenner S, Ruocco V. D-penicillamine-induced pemphigus foliaceus with autoantibodies to desmoglein-1. J Am Acad Dermatol 1998; 39 (1): 137-138. Go to original source... Go to PubMed...
    5. Cetkovská P. Autoimunitní bulózní dermatózy. Čes-slov. Derm. 2006; 81 (4): 188-196.
    6. Cummins DL, Mimoni D, Anhalt GJ, et al. Oral cyclophosphamide for treatment of pemphigus vulgaris et foliaceus. J Am Acad Dermatol 2003; 49 (2): 276-280. Go to original source... Go to PubMed...
    7. Deloach-Banta LJ, Tenaro LJ. Superficial erosions with some oozing and marked crusting. Pemphigus erythematosus (PE). Arch of Dermat 1993; 129(5): 633: 636-637. Go to original source... Go to PubMed...
    8. Goebeler M, Herzog S, Brocker EB, et al. Rapid response of treatment-resistant pemphigus foliaceus to the anti- CD20 antibody rituximab. Br J Dermatol 2003; 149: 899-901. Go to original source... Go to PubMed...
    9. Hirsch R, Anderson J, Weinberg JM, et al. Neonatal pemphigus foliaceus. J Am Acad Dermatol 2003; 49 (2): 187-189. Go to original source... Go to PubMed...
    10. Huh WK, Tada J, Fujimoto W, et al. Thyroid gland tumor, pemphigus foliaceus and myastenia gravis in the daughter of a woman with myastenia gravis. Clin Exp Dermatol 2001; 26 (6): 504-506. Go to original source... Go to PubMed...
    11. Inaoki M, Kaji K, Funuse S, et al. Pemphigus foliaceus developing after metastasis of cutaneous squamous cell carcinoma to regional lymph nodes. J Am Acad Dermatol 2001; 45 (5): 767-770. Go to original source... Go to PubMed...
    12. Kano Y, Shimosegawa M, Mizukawa Y, et al. Pemhigus foliaceus induced by exposure to sunlight. Report of a case and analysis of photochallenge-induced lesions. Dermatology 2000; 201 (2): 132-138. Go to original source... Go to PubMed...
    13. Marcusson JA, Bjarnason B, Shanwell A. Pemphigus foliaceus successfully controlled with plasma exchange during 10 years. Acta Derm Venerol 1998; 78: 295-296. Go to original source... Go to PubMed...
    14. Martel P, Loiseau P, Joly P, et al. Paraneoplastic pemphigus is associated with the DRB1 03 alele. J Autoimmun 2003; 20 (1): 91-95. Go to original source... Go to PubMed...
    15. Mimoni D, Anhalt G, Cummins DL, et al. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol 2003; 139 (6): 739-742. Go to original source... Go to PubMed...
    16. Narbutt J, Torzecja JD, Sysa-Jedrzejowska A, et al. Pemphigus foliaceus in an 11-year-old boy with dermatomyositis: simple coincidence or familiar immunological background? Br J Dermatol 2003; 148: 838-839. Go to original source... Go to PubMed...
    17. Nousari HC, Anhalt GJ. Pemphigus. In: Lebwohl MG, Heymann WR, Berth-Jones J, Coulson I. Mosby Elselvier 2006, 2nd ed.: 474-475.
    18. Nousari HC, Moresi M, Klapper M, et al. Nonendemic pemphigus foliaceus presenting as fatal bullous exfoliative erythroderma. Cutis 2001; 67 (3): 251-252. Go to PubMed...
    19. Scheinfeld NS, Howe KL, DiCostanzo DP, Craig E, Cohen SR. Pemphigus erythematosus associated with anti-DNA antibodies and multiple anti-ENA antibodies: a case report. Cutis 2003; 71(4): 303-306. Go to PubMed...
    20. Stanley JR. Pemphigus. In Freedberg IM, et al. Fitzpatrick´s Dermatology in general medicine. McGraw-Hill 2003, 6th ed.: 559-574.
    21. Takeshita K, Amano M, Shimizu T, et al. Thymoma with pemphigus foliaceus. Intern Med 2000; 39 (9): 742-747. Go to original source... Go to PubMed...
    22. Tomasini D, Cerri A, Cozzani E, et al. Development of pemphigus foliaceus in a patient with psoriasis: a simple coincidence? Eur J Dermatol 1998; 8 (1): 56-59.
    23. Vosmík F. Puchýřnaté choroby. Med Rev 1999; 6 (4): 8-11.
    24. White GM, Cox NH. Diseases of the skin. Mosby Elservier 2006; 2nd ed.: 319-339.
    25. Wojnarovska F, Venning VA, Burge SM. Immunobullous Diseases. In: Burns T, Breathnach S, Cox N, Griffiths Ch. Rook´s Textbook of Dermatology. Blackwell Science 2004, 7th ed., Vol. II: 41.1-41.59.
    26. Yamamoto S, Kanekura T, Gushi A, et al. A case of localized pemphigus foliaceus. J Dermatol 1996; 23 (12): 893-895. Go to original source... Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.